Alloisolithocholic Acid-d4
(Synonyms: AILCA-d4; AlloisoLCA-d4; β-hydroxy-5-Cholenoic Acid-d4; IsoalloLCA-d4; Isoallolithocholic Acid-d4) 目录号 : GC91985Alloisolithocholic Acid-d4用于GC-或LC-MS定量别异石胆酸的内标。
Cas No.:2410277-60-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Alloisolithocholic acid-d4 is intended for use as an internal standard for the quantification of alloisolithocholic acid by GC- or LC-MS. Alloisolithocholic acid is a metabolite of the secondary bile acid metabolite 3-oxo lithocholic acid (dehydrolithocholic acid).1 It is formed from 3-oxo lithocholic acid by gut microbiota.1 Alloisolithocholic acid (20 ?M) increases the association of the nuclear hormone receptor nerve growth factor IB (Nr4a1) to the gene encoding forkhead box protein P3 (Foxp3) in isolated mouse CD4+ T cells. It induces the differentiation of isolated mouse T cells into regulatory T cells (Tregs) and the production of mitochondrial reactive oxygen species (ROS) in isolated mouse CD4+ T cells when used at a concentration of 20 ?M.2 Alloisolithocholic acid (6 mg/kg) reduces hepatic bile flow and bile salt, cholesterol, and phospholipid secretion, as well as induces loss of microvilli and dilation of canaliculi in hepatocytes, markers of cholestasis, in rats.3 Fecal levels of alloisolithocholic acid are reduced in patients with Crohn’s disease or ulcerative colitis.1
References:
[1]. Li, W., Hang, S., Fang, Y., et al.A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1Cell Host Microbe29(9)1366-137.
[7]. e1369(2021).
[2]. Hang, S., Paik, D., Yao, L., et al.Bile acid metabolites control TH17 and Treg cell differentiationNature576(7785)143-148(2019).
[3]. Vonk, R.J., Tuchweber, B., Massé, D., et al.Intrahepatic cholestasis induced by allo monohydroxy bile acid in ratsGastroenterology80(2)242-249(1981).
| Cas No. | 2410277-60-8 | SDF | |
| 别名 | AILCA-d4; AlloisoLCA-d4; β-hydroxy-5-Cholenoic Acid-d4; IsoalloLCA-d4; Isoallolithocholic Acid-d4 | ||
| 化学名 | (5α)-3β-hydroxy-d4-cholan-24-oic acid | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C([2H])([2H])[C@@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| 分子式 | C24H36D4O3 | 分子量 | 380.6 |
| 溶解度 | DMSO: Slightly soluble: 0.1-1 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6274 mL | 13.1372 mL | 26.2743 mL |
| 5 mM | 0.5255 mL | 2.6274 mL | 5.2549 mL |
| 10 mM | 0.2627 mL | 1.3137 mL | 2.6274 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet